Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.78 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.65 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.65 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.65 |
| ▸ | NT5E | P21589 | 2/20 | 0.57 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | KRAS | P01116 | 3/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.51 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.50 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.50 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.50 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
| ▸ | DTYMK | P23919 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16678590 | 0.94 | POLB (0.82) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL18785118 | 0.94 | POLB (0.82) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL17117812 | 0.94 | POLB (0.82) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL48232 | 0.94 | POLB (0.82) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL1971161 | 0.94 | POLB (0.82) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL25171429 | 0.94 | POLB (0.82) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL20710403 | 0.93 | POLB (0.81) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL22053475 | 0.93 | POLB (0.81) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL20832619 | 0.93 | POLB (0.81) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL2231785 | 0.93 | POLB (0.81) | POLBP2RY2P2RY4P2RY6NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200325480-A1 | Antisense Oligonucleotides (ODN) Against SMAD7 and Uses Thereof in Medical Field | NOGRA PHARMA LTD (IE) | 2020-10-15 | — | — | US | claimed |
| US-10633660-B2 | Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field | NOGRA PHARMA LIMITED (IE) | 2020-04-28 | — | — | US | claimed |
| US-20190211336-A1 | Antisense Oligonucleotides (ODN) Against SMAD7 and Uses Thereof in Medical Field | GIULIANI INTERNATIONAL, LTD. (IE) | 2019-07-11 | — | — | US | claimed |
| US-20170268006-A1 | TOLL-LIKE RECEPTOR 9 ANTAGONIST AND METHODS OF USE THEREOF | IDERA PHARMACEUTICALS INC (US) | 2017-09-21 | — | — | US | claimed |
| US-9688993-B2 | Toll-like receptor 9 antagonist and methods of use thereof | IDERA PHARMACEUTICALS, INC. (US) | 2017-06-27 | — | — | US | claimed |
| US-20160237437-A1 | TOLL-LIKE RECEPTOR 9 ANTAGONIST AND METHODS OF USE THEREOF | NOVAQUEST CO-INVESTMENT FUND XV, L.P. | 2016-08-18 | — | — | US | claimed |
| WO-2016130832-A1 | TOLL-LIKE RECEPTOR 9 ANTAGONIST AND METHODS OF USE THEREOF | IDERA PHARMACEUTICALS, INC. (US) | 2016-08-18 | — | — | WO | claimed |
| US-8648186-B2 | Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field | NOGRA PHARMA LIMITED (IE) | 2014-02-11 | — | — | US | claimed |
| US-20130203839-A1 | ANTISENSE OLIGONUCLEOTIDES (ODN) AGAINST SMAD7 AND USES THEREOF IN MEDICAL FIELD | NOGRA PHARMA LIMITED (IE) | 2013-08-08 | — | — | US | claimed |
| US-20120136043-A1 | ANTISENSE OLIGONUCLEOTIDES (ODN) AGAINST SMAD7 AND USES THEREOF IN MEDICAL FIELD | NOGRA PHARMA LIMITED (IE) | 2012-05-31 | — | — | US | claimed |
| JP-4559411-B2 | — | — | 2010-10-06 | — | — | JP | claimed |
| US-7700757-B2 | for treatment of chronic inflammatory bowel disease, Crohn's disease and ulcerative colitis | GIULIANI INTERNAITONAL LIMITED (IE) | 2010-04-20 | — | — | US | claimed |
| EP-1608753-B1 | ANTISENSE OLIGONUCLEOTIDES (ODN) AGAINST SMAD7 AND USES IN MEDICAL FIELD THEREOF | GIULIANI INT LTD (IE) | 2008-12-10 | — | — | EP | claimed |
| US-20070167385-A1 | for treatment of chronic inflammatory bowel disease, Crohn's disease and ulcerative colitis | NOGRA PHARMA LIMITED (IE) | 2007-07-19 | — | — | US | claimed |
| US-20070042985-A1 | Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2007-02-22 | — | — | US | claimed |
| JP-2006521815-A | — | — | 2006-09-28 | — | — | JP | claimed |
| EP-1608753-A1 | ANTISENSE OLIGONUCLEOTIDES (ODN) AGAINST SMAD7 AND USES IN MEDICAL FIELD THEREOF | Giuliani International Limited (IE) | 2005-12-28 | — | — | EP | claimed |
| WO-2004087920-A1 | ANTISENSE OLIGONUCLEOTIDES (ODN) AGAINST SMAD7 AND USES IN MEDICAL FIELD THEREOF | GIULIANI INTERNATIONAL LIMITED (IE) | 2004-10-14 | — | — | WO | claimed |
| US-20200325480-A1 | Antisense Oligonucleotides (ODN) Against SMAD7 and Uses Thereof in Medical Field | NOGRA PHARMA LTD (IE) | 2020-10-15 | — | — | US | disclosed |
| WO-2004087920-A1 | ANTISENSE OLIGONUCLEOTIDES (ODN) AGAINST SMAD7 AND USES IN MEDICAL FIELD THEREOF | GIULIANI INTERNATIONAL LIMITED (IE) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170268006-A1 | TOLL-LIKE RECEPTOR 9 ANTAGONIST AND METHODS OF USE THEREOF | TLR9, TLR3, TLR7 | POLB 1909/4885P2RY2 126/4885P2RY4 261/4885 |
| US-20160237437-A1 | TOLL-LIKE RECEPTOR 9 ANTAGONIST AND METHODS OF USE THEREOF | TLR9, TLR3, TLR7 | POLB 1909/4885P2RY2 126/4885P2RY4 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.